Related Experiment Video
Updated: Jun 25, 2026

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection
Published on: February 20, 2020
Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?
Vered Schechner1, Vandack Nobre, Keith S Kaye
1Division of Epidemiology, Sourasky Medical Center, Tel Aviv, Israel. vereds@tasmc.health.gov.il
Background:
Pseudomonas aeruginosa is an uncommon cause of community-acquired bacteremia among patients without severe immunodeficiency. Because tension exists between the need to limit unnecessary use of anti-pseudomonal agents and the need to avoid a delay in appropriate therapy, clinicians require better guidance regarding when to cover empirically for P. aeruginosa. We sought to determine the occurrence of and construct a model to predict P. aeruginosa bacteremia upon hospital admission.
Methods:
A retrospective study was conducted in 4 tertiary care hospitals. Microbiology databases were searched to find all episodes of bacteremia caused by gram-negative rods (GNRs)
Results:
P. aeruginosa caused 6.8% of 4114 unique patient episodes of GNR bacteremia upon hospital admission (incidence ratio, 5 cases per 10,000 hospital admissions). Independent predictors of P. aeruginosa bacteremia were severe immunodeficiency, age >90 years, receipt of antimicrobial therapy within past 30 days, and presence of a central venous catheter or a urinary device. Among 250 patients without severe immunodeficiency, if no predictor variables existed, the likelihood of having P. aeruginosa bacteremia was 1:42. If >or= 2 predictors existed, the risk increased to nearly 1:3.
Conclusions:
P. aeruginosa bacteremia upon hospital admission in patients without severe immunodeficiency is rare. Among immunocompetent patients with suspected GNR bacteremia who have >or= 2 predictors, empirical anti-pseudomonal treatment is warranted.
Insights
Pseudomonas aeruginosa bacteremia is rare in hospitalized patients without severe immunodeficiency. Clinicians should consider empirical anti-pseudomonal treatment if 2 or more risk factors are present.
Area of Science:
- Infectious Diseases
- Clinical Microbiology
- Epidemiology
Background:
- Pseudomonas aeruginosa is an infrequent cause of community-acquired bacteremia, particularly in non-immunocompromised individuals.
- Clinical decisions regarding empirical anti-pseudomonal therapy are challenging due to the need to balance judicious antibiotic use with timely treatment.
- There is a need for improved guidance to identify patients at risk for P. aeruginosa bacteremia upon hospital admission.
Purpose of the Study:
- To determine the incidence of P. aeruginosa bacteremia at hospital admission.
- To develop a predictive model for identifying patients with P. aeruginosa bacteremia.
Main Methods:
- A retrospective study was conducted across four tertiary care hospitals.
- Microbiology databases were searched for Gram-negative rod (GNR) bacteremia within 48 hours of admission.
- Logistic regression analysis identified independent predictors of P. aeruginosa bacteremia.
Main Results:
- P. aeruginosa accounted for 6.8% of GNR bacteremia episodes at admission (5 cases per 10,000 admissions).
- Independent predictors included severe immunodeficiency, age >90 years, recent antimicrobial therapy, and presence of central venous or urinary devices.
- In patients without severe immunodeficiency, the risk of P. aeruginosa bacteremia increased from 1:42 to nearly 1:3 with two or more predictors.
Conclusions:
- P. aeruginosa bacteremia at hospital admission is uncommon in patients without severe immunodeficiency.
- Empirical anti-pseudomonal treatment is recommended for immunocompetent patients with suspected GNR bacteremia and two or more identified predictors.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

